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UbiquitinDynamic ubiquitination impacts on the degradation of proteins by the proteasome as well as on their effects
as signalling factors. Of the many cellular responses that are regulated by changes in ubiquitination, apoptosis
has garnered special attention. We have found that USP2a and USP2c, two isoforms of the ubiquitin-speciﬁc
protease USP2, cause cell death upon ectopic expression. We show that both USP2 isoforms can control the
ubiquitination status of many proteins but from a panel of potential targets only the protein level of RIP1
was increased by these enzymes. This effect is responsible for the activity of USP2a and USP2c to cause cell
death. Both enzymes likewise de-ubiquitinate TRAF2, a ubiquitin-ligase in the TNFR1 complex. Whilst this
and the similar sub‐cellular localisations of both enzyme isoforms indicate a substantial overlap of activities,
inactivation by RNAi revealed that only the knock-down of USP2c resulted in apoptosis, whilst targeting
USP2a did not have any consequence on the cells' survival. Consequently, we focussed our studies on
USP2a and found that TRAF2 inhibits USP2a's effect on K48- but not on K63-linked ubiquitin chains. Hence,
the ratio between USP2a and TRAF2 protein levels determines the cells' sensitivity to cell death.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The conjugation of ubiquitin to proteins controls numerous biochem-
ical reactions such as the maturation of precursor proteins, the degrada-
tion of unneeded, damaged or misfolded proteins and normal protein
turnover. Recently, it emerged that ubiquitination can also activate
various factors in signalling circuits [1]. Due to these multifarious
consequences ubiquitination plays a critical role in many biological pro-
cesses including cell proliferation, differentiation and apoptosis. Covalent
attachment of ubiquitin is highly regulated involving several enzymes
with their substrates being either mono- or poly-ubiquitinated. For the
latter, the ubiquitin molecules are generally linked through their lysine
residue at position 48 (K48) or 63 (K63). K63-linked ubiquitination
mediates signalling effects, whereas K48-conjugated ubiquitination
induces proteasomal degradation of the target proteins. Attachment of
ubiquitin is a reversible process and de‐ubiquitinating enzymes, orR1, tumour necrosis factor re-
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rights reserved.DUBs, can remove this moiety [2]. This speciﬁc and regulated reaction
inhibits the procession of proteins and/or impacts on their signalling ac-
tivities. Thus, DUBs play a crucial role in determining the cellular fates of
numerous proteins and in regulating various cellular functions [2].
Among the genes that we have isolated in a screen for apoptosis in-
ducers is the ubiquitin-speciﬁc protease USP2 [3]. The USP2 gene encodes
three different isoforms as a result of alternative splicing [3,4]. These
isoforms have different N-termini, but share an identical C-terminal cata-
lytic core, which contains the canonical isopeptidase Cys- and His-boxes
comprising the residues critical for catalysis. We have previously
shown that the 41 kDa USP2 isoform induces apoptosis [3] and that the
69 kDa USP2a isoform mediates the apoptosis signal of the TNF receptor
[5].
Here we investigated and compared the USP2a and USP2c
isoforms also known as isoforms 1 and 3 (http://www.uniprot.org/
uniprot/O75604), respectively. We found that both enzymes, which
differ only in their N-termini (Fig. 1A), induce apoptosis when ectop-
ically expressed. We show that USP2a and USP2c are targeting RIP1
kinase 1 (RIP1) whose accumulation is responsible for their ability
to cause apoptosis. Both enzyme isoforms also de‐ubiquitinate TNF
receptor-associated factor 2 (TRAF2), like RIP1 another component
of the TNFR1 complex. Whilst these USP2 isoforms share a consider-
able overlap of functions, only the knock-down of USP2c causes cell
death, no effect on cell survival is observed when USP2a is targeted
by RNAi. Finally, we found that TRAF2 acts as a counter-player of
USP2a suggesting that it is the ratio between USP2a and TRAF2 pro-
tein levels that confers sensitivity to cell death or survival.
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Fig. 1. USP2a and USP2c induce apoptosis when ectopically expressed.(A) Schematic representation of USP2a and USP2c. The N-terminal part comprising 258 amino acids, which is
speciﬁc for the USP2a isoform, is indicated by a white box. The 347 amino acid C-terminal domain (in black) possesses the canonical isopeptidase Cys, His, and Asp/Asn residues
critical for the enzymatic activity. USP2c is indicated below and shares the C-terminal domain but differs in its short N-terminal sequences (indicated by different shading). A point
mutation of the amino acid cysteine at position 276 into an alanine residue was used in this study to abolish the catalytic activity of USP2a [31]. For USP2c the corresponding C33
was mutated.(B) Wild type USP2a and USP2c but not their catalytic mutant C276A induce cell death after 48 h. MCF7 cells were transfected with a negative control plasmid coding
for luciferase (LUC), a positive control plasmid for Bax, or with a plasmid encoding USP2a or its enzymatically inactive mutant (C276A). After 48 h, cells were harvested and stained
with PI. Cell death was scored on the basis of DNA fragmentation (sub-G1 population) as measured by FACS analysis. Shown are the means of four independent experiments done in
duplicate for each construct. Bars represent means+/−SD. ***t-test, pb0.005 (top panel).(C) Wild type USP2a and USP2c but not their catalytic mutants induce apoptosis. 24 h
after transfection, PARP, an enzyme implicated in DNA damage and repair, is processed from its native 116 kDa to the 85 kDa form upon transfection of USP2a and USP2c but
not their mutants C276A and C33A as revealed by Western blotting (top panel). B-actin was used as a loading control (bottom panel).(D) USP2a and USP2c expression induce
caspase-8 activation. MCF7 cells were transfected with constructs coding for luciferase, USP2a, USP2c or their C276A and C33A mutants. 48 h post-transfection, caspase-8 activity
was quantiﬁed by a caspase-8 activity assay using FACS. Bars represent means+/−SD. *t-test, pb0.05.
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2.1. Reagents and antibodies
Human recombinant TNF was from Alexis Biochemicals (Enzo Life
Sciences, UK). MG132was fromCalbiochem (UK). Polyclonal andmono-
clonal anti-Haemagglutinin (HA), polyclonal anti-USP2a, polyclonaland monoclonal anti-Flag (M2), monoclonal β-actin, horseradish
peroxydase-conjugated (HRP) goat anti-rabbit were from Sigma-
Aldrich (UK). Monoclonal antibodies against RIP1 and TRAF2 were
purchased from BD Biosciences (UK). The polyclonal antibody against
USP2a (cterm L523) was obtained from Abgent (UK). Polyclonal anti-
PARP antibodies were supplied from Cell Signalling (UK). Anti-TRAF2
(H-249), -TRAF2 (F4), -RIP1 (H207), c-IAP2 (H85) and IκB (C-21)
1355A-L. Mahul-Mellier et al. / Biochimica et Biophysica Acta 1823 (2012) 1353–1365antibodies were from Santa Cruz Biotechnology (Tebu-Bio, UK). Anti-
ubiquitin, anti-ubiquitin (lysine K48), anti-ubiquitin (lysine K63) were
purchased from Millipore (UK). HRP goat anti-mouse antibody was
obtained from Jackson Laboratories (USA) and goat anti-rabbit Alexa
Fluor 555 or goat anti-mouse Alexa Fluor 488 antibodies were from
Molecular Probes (Invitrogen, UK).
2.2. DNA constructs
Mammalian expression vectors coding for human USP2a, human
TRAF2 and human RIP1 were from Origene (USA). Mammalian
expression vectors pRK5-HA coding for ubiquitin wild type (WT)
(Addgene plasmid 17608), ubiquitin K48 (Addgene plasmid 17605),
ubiquitin K63 (Addgene plasmid 17606) [6] were obtained from
Addgene (USA). cDNA coding for USP2a was ampliﬁed by PCR and
sublconed in the pCDNA3Δ (Invitrogen) in-frame with an HA tag se-
quence. The catalytically inactive mutant of USP2c (C33A) has been
engineered with the QuikChange Site-Directed Mutagenesis Kit from
Stratagene (UK). cDNAs coding for RIP and TRAF2 were ampliﬁed by
PCR and sub‐cloned in the pci vector (gift from Remy Sadoul, Inserm
U836, Grenoble, France) in-frame with an Flag tag sequence.
2.3. Cell culture and plasmid transfection
293T, MCF7 [7], HeLa, 3T3, 3T3 RIP−/−, MEF WT and MEF TRAF2−/−
cells were maintained in DMEM (Invitrogen, UK) containing 10% FCS
(Sigma, UK), 2 mM Glutamine (Invitrogen), 100 μg/ml streptomycine,
100 U/ml penicillin (Invitrogen), and sodium pyruvate (Invitrogen).
293T and 3T3 cells were transfected using Superfect (Qiagen, UK),
MCF7, HeLa andMEFs cells were transfectedwith Effectene (Qiagen) fol-
lowing the manufacturer's instructions. MEF WT and MEF TRAF2−/−
were a gift from Dr Tak Mak (Toronto, Canada).
2.4. Quantiﬁcation of cell death
The percentage of the SubG1 cell population was used to quantify
cell death. The supernatant and the adherent cells were harvested
and resuspended in lysis buffer (0.1% sodium citrate and 0.1% Triton
X-100 in PBS) containing propidium iodide (PI, Sigma, 20 μg/ml).
Cells were then analysed using FACS (BD Biosciences) with the
CellQuest programme (BD Biosciences).
2.5. Detection of active caspase-8
CaspaTagTM ﬂuorescein caspase‐8 activity kit (Millipore, UK) al-
lows the detection of active caspase-8 in living cells through the use
of a fam-LETD-fmk. This probe passively enters cells and binds irre-
versibly to the active caspase-8. 48 h after transfection, MCF7 cells
were harvested and incubated for 1 h at 37 °C with fam-LETD-fmk
and with PI in accordance with the supplier's instructions. Fluorescein
emission was analysed by FACS.
2.6. Immunoﬂuorescence
HeLa cells or MCF7 cells, seeded on coverslips (CS), were trans-
fected with Effectene (Qiagen) by USP2a-HA or USP2c-HA with Flag-
RIP1 or Flag-TRAF2 or with DsRed-ER (endoplasmic reticulum), YFP-
mito (mitochondria), LC3-GFP, YFP-endosomes or CFP-Golgi with
Effectene and grown for 24 h. Cells were then ﬁxed in 4% paraformal-
dehyde in PBS for 20 min at 4 °C. After a blocking step with 3% BSA in
Tris–HCl 50 mM, NaCl 155 mM, pH 7.6 and 0.02% saponine (TBSS) for
30 min at room temperature (RT), cells were incubated with the pri-
mary antibody for 1 h at RT. Cells were rinsed ﬁve times in TBSS and
then incubated with the secondary anti-rabbit Alexa Fluor 555 anti-
body or the anti-mouse Alexa Fluor 488 antibody at a dilution of
1/500 in TBSS. Cells were washed ﬁve times in TBSS and incubated30min at RT in DAPI at 2 μg/ml (Invitrogen), before being mounted
in polyvinyl alcohol mounting medium with DABCO (Sigma). Cells
were examined with confocal laser-scanning microscope (Leica) with
a 63× objective and analysed with LAS AF software.
2.7. Immunoprecipitation and Western blotting
24 h after transfection, MCF7 or MEF cells were lysed in RIPA buffer
(150 mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% deoxycholate, 0.1%
SDS and 2× proteases inhibitor mixture (Sigma)). Cell lysates were
cleared by centrifugation at 4 °C for 15 min at 13 000 rpm followed
by two incubations of 30 min G-Sepharose beads (Amersham Biosci-
ences, UK). Cell lysates were incubated overnight at 4 °C with 3 μg of
anti-Flag monoclonal M2 Ab, 3 μg of anti-HA monoclonal or 15 μg of
anti-Nterm USP2a polyclonal Ab or with polyclonal anti-RIP1 or
-TRAF2 at 1/100. Immune complexes were precipitated with Proteine
G-Sepharose and the beads were washed with RIPA buffer. Immuno-
precipitated proteins were separated in a 10% SDS-PAGE and trans-
ferred onto a PVDF membrane (Millipore, UK). Membranes were
blocked with 3% BSA in PBS containing 0.1% Tween and incubated
with the appropriate antibodies. Speciﬁc signals were revealed by the
ECL detection reagent (Pierce, UK).
2.8. In vivo ubiquitination assay
USP2a or the catalytically inactivemutant USP2a C276A and plasmids
coding for HA-ubiquitin (WT), HA-ubiquitin (K48) or HA-ubiquitin
(K63) were transfected in 293T. 24 h post-transfection, cells were treat-
ed withMG132 (10 μM) for 4 h or with TNF (20 ng/ml) for 15 min. Cells
were harvested, lysed and boiled 5 min in 1% SDS (v/v) to remove all
non-covalently associated proteins. Lysates were diluted 1:10 in RIPA
buffer supplemented by 2× protease inhibitor mixture (Sigma). TRAF2
or RIP1was immunoprecipitated using an anti-RIP1 or an anti-TRAF2 an-
tibody as described above. Proteins bound to the beads were then eluted
in Laemmli buffer and subjected to immunoblot analysis.
2.9. RIP1 and TRAF2 downregulation by siRNA
The Accell SMARTpool siRNA used to downregulate RIP1 (E-004445-
00), the Accell Non-targeting Pool (D-001910-10-20) and the Accell
siRNA Delivery Medium were purchased from Dharmacon (UK). MCF7
cells were transfected following the Accell siRNA delivery protocol in ac-
cordance with the supplier's instructions. 72 h post-transfection, cells
were split and seeded in 24 wells plate. The following day, MCF7 were
transfected by plasmids coding for USP2a or Luciferase. 48 h post-
transfection, cell death was quantiﬁed by FACS. The ON-TARGETplus
SMARTpool siRNA used to downregulate TRAF2 (L-005198-00-0005)
was purchased from Dharmacon. MCF7 cells were transfected with
siRNAs using Effectene. After 72 h, MCF7 were left untreated or treated
for 24 h with TNF-α (100 ng/ml). The percentage of the SubG1 cell pop-
ulation was used to quantify cell death.
2.10. USP2a downregulation by shRNA in MCF7 cells
The USP2a shRNA was sub-cloned downstream of the human H1
promoter in the pSuper vector (Oligoengine, Seattle, WA, USA). MCF7
cells were transfected by USP2a or scrambled shRNA/pSuper by
effectene. The sequences of the synthetic oligonucleotides (Invitrogen,
UK) used for USP2a shRNA construct were the following:
5′-GATCCCC GCCGGTCCCCACCAGCAGCTTCAAGAGAGCTGCTGGTGG-
GGACCGGCTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAAGCCGGTCCC-
CACCAGCAGC TCTCTTGAAGCTGCTGGTGGGGACCGGCGGG-3′
The sequences of the synthetic oligonucleotides used for scrambled
shRNA construct were:
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Fig. 3. USP2a and USP2c target K48 and K63 ubiquitin chains in a broad range of substrates but lead to the speciﬁc accumulation of RIP1 for apoptosis induction.(A) Schematic represen-
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ubiquitination was detected in a Western blot with an antibody against HA (bottom panel). The expression of the various constructs was conﬁrmed in an additional protein blot using
an antibody against USP2. Actinwas used as a loading control.(C) Ectopic USP2a andUSP2c expression lead to RIP1 accumulation.MCF7 cells were transfectedwith the indicated plasmids
for USP2a orUSP2c or a plasmid coding for luciferase. 24 h post-transfection, cellswere lysed and proteins separated by SDS-PAGE. The endogenous protein levels of RIP1, IAP2, TRAF2 and
IκB-αwere assessed by immunoblotting using speciﬁc antibodies.(D) Accumulation of RIP1 induces apoptosis in the MCF7 cell line. MCF7 cells were transfected with a negative control
plasmid coding for luciferase (LUC), a positive control plasmid for Bax or with a plasmid encoding RIP1. After 48 h, cells were harvested. MCF7 cells were stainedwith PI and the percent-
age of cell death was scored on the basis of DNA fragmentation (sub-G1 population) as measured by FACS analysis. Data shown in the histogram are the means of three independent ex-
periments done in duplicate for each construct. Bars represent means+/−SD. ***t-test, pb0.005.(E) USP2a's and USP2c's pro-apoptotic effect depend on RIP1. MCF7 cells were
transfected with siRNA against RIP1 or with a control siRNA sc. 72 h post-transfection, cells were harvested and stained with PI to quantify cell death (left panel). RIP1 downregulation
was conﬁrmed byWestern blot (insert). Four days after siRNA transfection, cells were transfected with an expression plasmid for Luc, USP2a or USP2c, harvested 48 h later, and stained
with PI to determine cell death (right panel). Shown are the means of three independent experiments done in duplicate for each construct. Bars are means+/−SD. **t-test, pb0.01.
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TGTGCGAGGGCTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAA GCCCTC-
GCACACGGCACCG TCTCTTGAA CGGTGCCGTGTGCGAGGGC GGG-3′2. Localisation of USP2a and USP2c.Hela cells were transfected with plasmids encod
doplasmic reticulum), endosome-YFP or LC3-GFP. 24 h after transfection, the proteins of
ence, respectively.The annealed oligonucleotides were ligated into the BglII–HindIII
cleavage site of the pSuperGFP vector linearised with the same restric-
tion enzymes. MCF7 cells were transfected by USP2a or scrambleding USP2a-HA (A) or USP2c-HA (B), YFP-mito (mitochondria), Golgi-CFP, ER-DsRed
interest and cellular organelles were detected by immunoﬂuorescence and direct ﬂuo-
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of USP2a was checked by Western blot for the protein expression level
or by semi-quantitative RT-PCR for the mRNA expression level.2.11. Detection of active caspase‐8
CaspaTagTM ﬂuorescein caspase‐8 activity kit (Millipore, UK)
allows the detection of active caspase-8 in living cells through the use of
a fam-LETD-fmk. This probe passively enters cells and binds irreversibly
to the active caspase-8. 36 h after transfection,MCF7 cells were harvested
and incubated for 1 h at 37 °Cwith fam-LETD-fmk in accordancewith the
supplier's instructions. Fluorescein emission was analysed by FACS.2.12. Autophagy assay
MCFwere transfected using jetPEI according to the manufacturer's
protocol. 22 h post‐transfection, autophagy was induced by treating
the beta-galactosidase transfected cells with 25 mM ammonium chlo-
ride [8–10] for 2 h (positive control for inducing-autophagy). Cells
were then harvested with RIPA buffer and 20 ug of each sample was
loaded onto 12% SDS-PAGE gel.2.13. Statistical analysis
Statistical analysis was performed using the unpaired student's
t-test. Data were regarded as statistically signiﬁcant if pb0.05 based
on student's t-test.3. Results
3.1. USP2a and USP2c induce apoptosis
Upon transfection of expression vectors for USP2a and USP2c
(Fig. 1A) the quantiﬁcation of the cell populationwith sub-G1 DNA con-
tent indicated that both constructs induced cell death in MCF7 cells,
whereas constructs encoding point mutations in the catalytic centre
(C276A or C33A) were inactive (Fig. 1B). In order to verify the mode
of cell death as apoptotic, using Western blotting we conﬁrmed the
cleavage of PARP, a substrate for caspases (Fig. 1C). Moreover,
expression of USP2a and USP2c but not of their enzymatically inactive
mutants was sufﬁcient to trigger caspase-8 activation (Fig. 1D).3.2. Sub‐cellular localisation of USP2a and USP2c
In order to get an indication of the relevant substrates for their cell
death activities we analysed the sub-cellular localisation of USP2a and
USP2c by immunoﬂuorescence. Only in HeLa cells transfected with
USP2a we observed that it localised to discrete perinuclear structures,
which neither coincided with mitochondria, the Golgi, nor with
endosomes but were adjacent to the ER (Fig. 2A). A very similar
cellular distribution was observed with USP2c even though the overlap
with ER structures was less pronounced (Fig. 2B). In MCF7, USP2a and
USP2c didn't colocalise either with any of the sub-cellular compart-
ments as shown in Supplementary Fig. S1. We also speciﬁcally
addressed the question whether USP2a and USP2c cause autophagy, a
cellular response that can lead to cell death under certain conditions.
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were transfected with the expression plasmids for USP2c or its catalytically inactive mutant C33A together with a plasmid coding for WT ubiquitin-HA or the K63 or K48 ubiquitin-
HA mutants. 24 h post-transfection, cells were treated with MG132 (10 μM) for 4 h (for K48, left panels) or with TNF (20 ng/ml) for 15 min (for K63, right panels). The cell lysates
were immunoprecipitated (IP) with an anti-TRAF2 antibody and blots probed with the indicated antibodies.
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autophagy. The protein blot in Supplementary Fig. S2 indicates a pro-
nounced processing of this protein with ammonium chloride [8].shRNAα : 
USP2
Actin
Sc US
P2
a
0
10
20
30
40
50
60
70
USP2ashRNAα : Sc USP2c
%
 o
f c
el
l d
ea
th ***
Sc US
P2
c
-40
-40
-40
-70
MW MW
Fig. 6. Downregulation of USP2c but not USP2a causes cell death. MCF7 cells were
transfected with shRNA constructs against USP2a and USP2c and were assessed for
cell death by PI staining after 48 h. The insert shows the reduction of the protein levels
in a Western blot.3.3. RIP1 is a target of USP2a and USP2c for apoptosis induction
For an in vivo de‐ubiquitination assay wild type (WT) USP2a and
USP2c or its C276A and C33A mutants were transfected together
with HA-tagged, wild type or mutants of ubiquitin that solely harbour
an intact lysine either in position 48 (K48) or in position 63 (K63)
(Fig. 3A). Western blotting against all HA-ubiquitin conjugated pro-
teins in whole cell lysates revealed that, like USP2a [5], USP2c is a
de‐ubiquitining enzyme that is able to remove WT ubiquitin chains
and also both poly‐ubiquitin chains (K48 mutant and K63 mutant)
from a broad range of proteins (Fig. 3B). This effect strictly depends
on the integrity of the cysteine residues 276 and 33, respectively, in
the catalytic core of the proteins (Fig. 1A). We used protein blots to
investigate whether several candidate proteins, known to be subject
to ubiquitination, are stabilised by USP2a or USP2c expression. As
USP2a and USP2c could activate caspase-8 (Fig. 1D) and USP2a
mediates the TNF response [5], we focussed on factors of the extrinsic
apoptosis pathway, which is the main, though not exclusive, signalling
route of these factors [11]. In contrast to the wide range of substrates
indicated by the de‐ubiquitination assay (Fig. 3B), we found that
among the proteins tested only RIP1 signiﬁcantly (Fig. 3C) accumulated
after USP2a and USP2c transfection. As we observed that the increase
in RIP1 levels can induce apoptosis in MCF7 cells (Fig. 3D), we wanted
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knocked down RIP1 using RNA interference and assessed apoptosis
upon USP2a and USP2c expression. RIP1 downregulation itself had no
effect on the viability of the cells (Fig. 3E, left panel), but it reduced
the pro-apoptotic effect of USP2a and USP2c by about 50% (Fig. 3E,
right panel). A similar effect was observed when apoptosis was quanti-
ﬁed by a caspase-8-speciﬁc assay (Supplementary Fig. S3). Initial
evidence for a functional connection between USP2a or USP2c and
RIP1 was provided when we analysed their interaction by immunopre-
cipitation. Lysates from USP2c-HA- and RIP1-FLAG- transfected cells
were immunoprecipitated with an anti-HA antibody. Western blot
analysis revealed the presence of RIP1, suggesting the existence of a
complex containing both proteins (Fig. 4A). We observed a similar
effect previously with USP2a [5]. In order to validate that RIP1 is also
a direct target for USP2c, we used an in vivo de-ubiquitination assay.
We co-transfected Flag-RIP1, USP2c and Ubiquitin WT-HA, or its
mutants K48-HA or K63-HA. Cells were harvested, lysed and boiled
5 min in 1% SDS (v/v) (denaturating dissociation buffer) to dissociate
any non-covalently bound proteins. Cell lysates were immunopreci-
pitated with an anti-RIP1 antibody and a subsequent Western blot
revealed the presence of HA-tagged ubiquitin variants. The left panel
of Fig. 4B shows that overexpressedWT USP2c but not its C33Amutant
efﬁciently released K48-linked ubiquitin chains from endogenous RIP1
in cells pre-treated with the proteasome inhibitor MG132. Similar re-
sults were previously obtained for USP2a [5]. Hence, we believe that
the observed accumulation of RIP1 (Fig. 3C) is due to the enzymatic ac-
tivity of USP2a and USP2c on K48 ubiquitin chains of this protein. This
increase of RIP1 is fatal for MCF7 cells since its overexpression leads to
cell death in those cells (Fig. 3D). As RIP1 is also conjugated to K63
ubiquitin chains upon TNF-α application [12,13] and since USP2a and
USP2c possess a K63-linked de‐ubiquitinase activity (Fig. 3B and ref
[5]), we speculated that USP2c has also an effect on K63 ubiquitin
chains attached to RIP1. When we performed the in vivo de-ubiquitin
assay for K63 chains upon TNF-α treatment, we detected an efﬁcient
removal of such chains from RIP1 (Fig. 4B, right panel). A similar ac-
tivity was previously uncovered for USP2a [5].3.4. USP2a and USP2c target TRAF2
The ubiquitin ligase TRAF2 is principally responsible for attaching
K63 ubiquitin chains to RIP1, which can trigger the survival pathway
via the activation of the inducible transcription factor NF-κB by TNF
[12,14]. TRAF2 itself, on the other hand, is also ubiquitinated on K48
[15] and K63 chains [5] and the conjugation with K63 ubiquitin
chains is required for its activity on RIP1 [16–18]. To explore a
potential interaction between USP2c and TRAF2, we conducted a co-Fig. 7. TRAF2 inhibits the de‐ubiquitination activity of USP2a on K48 ubiquitin chains and c
RIP1 levels. MCF7 cells were transfected with shRNA plasmid against USP2a or with a contr
cells were lysed and proteins separated by SDS-PAGE. The endogenous protein levels of RI
were transfected with scramble (sc) siRNA or siRNA against USP2a and with a plasmid co
MG132 for 4 h before they were lysed in the denaturating dissociation buffer. Endogenou
using antibodies speciﬁcally designed against the K48 ubiquitin chains. (B) TRAF2−/− ME
MEF cells were transfected with a control plasmid coding for luciferase (LUC), with a
transfection, cells were harvested and stained with PI to determine apoptosis with the sub
duplicate for each construct. Bars indicate means+/−SD. *t-test, pb0.05. (C) TRAF2 co-exp
mulation. MCF7 cells were transfected with the indicated expression vector for USP2a, a plas
stained with PI to assess cell death. Shown are the means of three independent experime
pb0.01. To determine the effect on the RIP1 protein level 24 h post-transfection the MCF7
protein levels of RIP1 were assessed by immunoblotting (bottom panels). (D) MCF7 cells w
luciferase (LUC) or for WWP1. 48 h post-transfection, cells were harvested and stained w
done in duplicate for each construct (left panel). Bars +/−SD. * pb0.05. (E) Increasing TRA
fected with the indicated plasmid ratios of USP2a and TRAF2. 48 h post-transfection, cells w
independent experiments performed in duplicate for each construct (top panel). The prote
loading control (bottom panel). (F) TRAF2 inhibits USP2a activity. MCF7 cells were tran
ubiquitin-HA, K48 ubiquitin-HA (K48) or K63 ubiquitin-HA. Overall protein ubiquitination w
sion were conﬁrmed in an additional protein blot using the appropriate antibody. Actin waimmunoprecipitation between USP2c-HA and endogenous TRAF2.
As shown in Fig. 5A, left panels Western blots of the immunoprecipi-
tates pulled down with an anti-HA antibody revealed an association
between TRAF2 with USP2c. Co-immunoprecipitations with deletion
mutants indicated that the RING domain in TRAF2 is required for
this association (Fig. 5A, right panels). A similar interaction was
uncovered for USP2a [5]. In an in vivo de-ubiquitination experiment
we determined the enzymatic effects of USP2c on TRAF2 and ob-
served the efﬁcient de-conjugation of K63-linked ubiquitin chains
from immunoprecipitated TRAF2 (right panels, Fig. 5B). K48 ubiquitin
chains, on the other hand, were not removed from TRAF2 (Fig. 5B, left
panels). Similar results were obtained for USP2a [5].
3.5. Downregulation of USP2c but not USP2a causes cell death
In order to determine the function of both USP2 isoforms we used
RNAi to speciﬁcally downregulated them. Surprisingly, USP2c reduc-
tion led to apoptosis as measured by FACS whereas USP2a knock-
down did not result in cell death (Fig. 6) and even protected against
TNF-induced cell death [5]. A similar effect was observed when apo-
ptosis was quantiﬁed by a caspase-8-speciﬁc assay (Supplementary
Fig. S4). Consequently, we focussed our subsequent investigations
on USP2a.
3.6. TRAF2 counteracts USP2a
RIP1 knock-out has been shown to inhibit NF-κB activation and
sensitise cells to apoptosis [19]. Since RIP1 can be a substrate for
USP2a and USP2c on K48-linked ubiquitin chains (Fig. 4 and Ref.
[5]), USP2 downregulation should reduce the RIP1 protein level.
Since USP2c inhibition caused cell death (Fig. 6), we perform the
following experiments only with USP2a. When we targeted USP2a by
shRNA, we did not observe an effect on the endogenous RIP1 level
(Fig. 7A, top panels). Also, the knock-down of USP2a did not affect
the level of the ubiquitin-K48 chains on the endogenous RIP1
(Fig. 7A, bottom panels). Hence, we speculated that the activity of en-
dogenous USP2a on K48-linked ubiquitin chains of RIP1 is restrained
by one or more inhibitors. TRAF2 was the prime candidate for such
an inhibitor as upon its co-transfection with USP2a no release of K48-
linked ubiquitins was observed (Fig. 5B). Since apoptosis following
USP2a transfection depends on its effect on K48 ubiquitin chains linked
to RIP1 (Figs. 1, 2), we ﬁrst assayed cell death in MEF TRAF2−/− cells.
In accordance with TRAF2 functioning as a speciﬁc USP2a inhibitor we
observed an increase of cell death upon USP2a transfection in those
cells (Fig. 7B). We also detected that TRAF2 co-expression in MCF7
cells signiﬁcantly decreased the apoptotic effect of USP2a (Fig. 7C, topounteracts apoptosis induction. (A) Downregulation of USP2a does not lead to altered
ol scrambled (sc) shRNA plasmid. 48 h post-transfection, MCF7 sc- and shRNA USP2a-
P1 were assessed by immunoblotting using a speciﬁc antibody (top panels).293T cells
ding for ubiquitin K48-HA. The cells were pre-treated with the proteasome inhibitor
s RIP1 was pulled-down and the presence of ubiquitin was detected by Western blot
F cells are more sensitive to USP2a expression than WT cells. WT MEF and TRAF2−/−
positive control plasmid for Bax, or with a plasmid coding for USP2a. 48 h post-
-G1 cell population. Shown are the means of three independent experiments done in
ression protects cells against the pro-apoptotic effect of USP2a and inhibits RIP1 accu-
mid coding for luciferase or for TRAF2. 48 h post-transfection, cells were harvested and
nts done in duplicate for each construct (top panel). Bars are means+/−SD. **t-test,
cells were lysed in RIPA buffer and proteins separated by SDS-PAGE. The endogenous
ere transfected with the indicated expression vector for USP2a, a plasmid coding for
ith PI to assess cell death. Shown are the means of three independent experiments
F2 expression counteracts apoptosis by overexpressed USP2a. MCF7 cells were trans-
ere harvested and stained with PI to assess cell death. Shown are the means of three
in levels of the respective construct were assessed by immunoblotting with actin as a
sfected with USP2a and luciferase or TRAF2 together with plasmids coding for WT
as detected in a Western blot with an antibody against HA. USP2a and TRAF2 expres-
s used as a loading control.
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Fig. 8. The ratio of USP2a and TRAF2 determine the apoptosis sensitivity to TNF.
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tively or with a scrambled control siRNA (sc) (top panels). 48 h post-transfection, cells
were treated overnight with TNF (100 ng/ml). Cells were harvested and stained with PI
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iments done in duplicate for each construct. Bars indicate means+/−SD. *t-test, pb0.05.
(B) Effect of TRAF2 knock-out on RIP1 levels. The endogenous protein levels of RIP1 was
assessed by immunoblotting using a speciﬁc antibody in MEF WT and MEF TRAF2−/−.
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(Fig. 7C, bottom panel). A similar effect was observed when apoptosis
was quantiﬁed by a caspase-8-speciﬁc assay (Supplementary Fig.
S5A). Of note, RIP1 was reduced to its normal level when USP2a and
TRAF2were co-transfected at a ratio of 1:1. In contrast, therewas no ef-
fect on cell death by USP2a when the WW domain containing E3
ubiquitin protein ligase 1 (WWP1) was co-transfected showing the
speciﬁcity of this effect (Fig. 7D, Supplementary Fig. S5B). We also
observed the successive reduction of USP2a-induced apoptosis when
increasing amounts of TRAF2 were titrated into the transfection mix
(Fig. 7E, Supplementary Fig. S5C). For an in vivo de‐ubiquitiation
assay USP2a, Flag-TRAF2 and ubiquitin-HA were co-transfected and
the level of ubiquitinated proteins in whole cells lysates were analysed
by Western blot. Fig. 7F shows that only the activity of USP2a on K48-
linked ubiquitin chains was repressed by TRAF2. In contrast, its activity
on ubiquitin chains conjugated via K63 residues was unaltered. In a
previous study we found that USP2a mediates the apoptosis signal
via the K63 ubiquitin chains in TRAF2 and RIP1 [5]. This and our new
experiments suggested that it is the ratio between USP2a and TRAF2
protein levels and their competition on K63-linked ubiquitin chains
that confer sensitivity to cell death by TNF. Consequently, we down-
regulated TRAF2 (Fig. 8A right hand top panel) or USP2a (Fig. 8A left
hand top panel) and recorded apoptosis upon TNF-α stimulation.
Fig. 8A reveals that whilst USP2a downregulation rendered cells resis-
tant to TNF as observed in our previous study [5], reduction of TRAF2
sensitised them to apoptosis. We observed the same effect in HeLa
cells (data not shown) and also when apoptosis was quantiﬁed by a
caspase-8-speciﬁc assay (Supplementary Fig. S6). When we investigat-
ed the level of RIP1 in TRAF2 KD cells in comparison with WT cells, we
did not observe a difference (Fig. 8B). The inhibition activity of TRAF2on
USP2a necessitates a co-localisation. Hence, we tested the sub-cellular
localisation of endogenous USP2a with TRAF2. As shown in Fig. 9A we
have observed a considerable overlap of the signals, which was further
increasedwhen the TNFwas applied to the cells. With USP2a being able
to stabilise RIP1, we also performed this experiment with the combina-
tion of those two factors and likewise observed a co-localisation of
endogenous RIP1 and USP2a, which increased upon TNF treatment
(Fig. 9B). Also, in co-transfected cells USP2a redistributed and co-
localised with RIP1 throughout the cytosol (Fig. 9C). This localisation
change of USP2a was not a consequence of apoptosis as revealed by
the application of the caspase inhibitor zVAD (data not shown). We
also performed immunoﬂuorescence of transfected USP2a and TRAF2
in co-transfection experiments (Fig. 9D), which likewise revealed a
co-localisation.4. Discussion
Our study shows that both isoforms of USP2, the long splice variant
USP2a and the short variant USP2c, target RIP1 whose accumulation
is responsible for the activity of the enzymes to cause cell death.Fig. 9. Localisation of endogenous USP2a, RIP1 and TRAF2 with and without TNF-α applicatio
endogenous USP2a and RIP1 were discovered with suitable antibodies and the cells counter
tion were overlaid (8 left hand panels) to show the special overlap of their staining patter
software. Channels for USP2a (green) and RIP ﬂuorescent signals (red) were merged a
colocalisation rate indicates the extent of colocalisation in % (right panel). Shown are the
means+/−SD. ***t-test, pb0.005.(B) Localisation of endogenous USP2a and TRAF2 with and
able antibodies and the cells counterstained with DAPI. The signals speciﬁc for TRAF2 and
special overlap of their staining patterns. Right hand panel: colocalisation of USP2a and TR
ﬂuorescent signals (red) were merged and pixels exceeding threshold intensities in both ch
% (right panel). Shown are the means of three independent experiments. Representative cells
MCF7 cells were co-transfected with expression plasmids for Flag-RIP1 and USP2a-HA. 24 h l
DAPI. The signals speciﬁc for RIP1 and USP2a were overlaid (right hand panel) to show the cha
are shown.(D) TRAF2 and USP2a co-localise. MCF7 cells were co-transfected with expression v
stained with the appropriate antibodies and counterstained with DAPI to reveal the nucleus. T
co-localisation of TRAF2 and USP2a. Representative cell stainings are shown.Whilst both share many additional features such as its second target
TRAF2 and their sub-cellular localisation in the cell when ectopically
expressed, the difference in the N-terminus of the isoforms is revealed
when the genes are speciﬁcally inactivated: Fig. 6 shows that the
reduction of USP2c, but not USP2a, induced apoptosis. Even though
other causes cannot formally be excluded, the most likely explanation
is that both isoforms differ in their range of substrates. Indeed, the
N-termini of DUBs have been shown to be responsible for the substrate
speciﬁcity [20]. It is conceivable that USP2c is responsible to ensure a
sufﬁcient high level of an anti-apoptotic protein, which when USP2c
is inactivated, is reduced and apoptosis ensues. Hence, USP2a onlyn. (A) Localisation of endogenous USP2a and RIP1 with and without TNF treatment. The
stained with DAPI. The signals speciﬁc for RIP1 and USP2a with and without TNF addi-
ns. Right hand panel: colocalisation of USP2a and RIP1 was analysed using the LAS AF
nd pixels exceeding threshold intensities in both channels depicted in white. The
means of three independent experiments. Representative cells are shown. Bars are
without TNF application. The endogenous USP2a and TRAF2 were discovered with suit-
USP2a with and without TNF addition were overlaid (8 left hand panels) to show the
AF2 was analysed using the LAS AF software. Channels for USP2a (green) and TRAF2
annels depicted in white. The colocalisation rate indicates the extent of colocalisation in
are shown. Bars are means+/−SD. ***t-test, pb0.005.(C) USP2a co-localises with RIP1.
ater cells were immunostained with the appropriate antibodies and counterstained with
nge in the USP2a staining pattern in cells co-expressing RIP1. Representative cell stainings
ectors for Flag-TRAF2 and WT USP2a-HA. 24 h post-transfection the cells were immuno-
he signals of the speciﬁc stainings were then overlaid in the right hand panel to show the
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1364 A-L. Mahul-Mellier et al. / Biochimica et Biophysica Acta 1823 (2012) 1353–1365possesses pro-apoptotic functions, both at its endogenous level to me-
diate the conversion of the anti-apoptotic complex I into the pro-
apoptotic complex II of the TNF receptor complex [5] and its effect on
RIP1 accumulation upon its ectopic expression (this study). USP2c, on
the other hand, has both pro- and anti-apoptotic effects when
upregulated and at its endogenous level, respectively. Consequently
the expression level of USP2c must be tightly regulated. Such an effect
is not without precedence, caspase-2 can induce apoptosis when
upregulated and also when inactivated by homologous recombination
in mice [21,22].
In this study we used transfection and overexpression of the USP2
isoforms for various experiments. This scenario is relevant for cell
death induction in muscular diseases (such as cardiomyopathy [23]
or muscular dystrophy [24]) or neuromuscular diseases (like
Huntington's disease [25] or spastic paraplegia [26]) in which the
USP2 gene has been found to be strongly upregulated (E-MTAB-62,
E-GEOD-3307 from Atlas EMBL-EBI), even though the data do not
allow to distinguish which of the isoforms is affected.
How can USP2a and USP2c lead to the de-ubiquitination of many
substrates (Fig. 3B) and at the same time only few potential target
proteins accumulate (Fig. 3C)? A possible explanation is that the de-
ubiquitination by the USP2 isoforms is not complete and the respec-
tive target proteins are still degraded via the proteasome. Hence,
the USP2 variants seem to cause the activation of apoptosis pathways
by the speciﬁc stabilising of their RIP1 substrate.
Based on the pro-apoptotic effect when USP2c was targeted by
RNAi, we focussed our investigations on USP2a and found that whilst
downregulation of USP2a has effects on cellular consequences of
TNF-α connected with K63-linked ubiquitin chains such as apoptosis
and NF-κB activation [5], the stability of the RIP1 protein that is
controlled by K48-linked ubiquitin chains remains unaffected
(Fig. 7A). This is of importance as abrogation of RIP1 sensitises cells
for apoptosis and inhibits NF-κB activation [19]. Hence, if USP2a was
contributing to the endogenous RIP1 level, this enzyme would also
have an anti-apoptotic effect. We concluded that this activity, which
nevertheless is revealed upon USP2a overexpression (Fig. 3C), must
be inhibited and speculated that TRAF2 functions as the inhibitor as
its co-transfection abrogated USP2a's activity on K48-ubiquitin chains
([5] and Fig. 7F). In fact, co-transfection of TRAF2 with USP2a at a
ratio of 1:1 restored RIP1 to the endogenous expression level
(Fig. 7C).
TRAF2 is a ubiquitin ligase but it only possesses a ligase activity on
the K63-ubiquitin chains on RIP1 [27]. Hence, the restoration of the
RIP1 protein level cannot be the consequence of the enzymatic
activities of TRAF2 and USP2a competing for the K48 ubiquitin chains
of RIP1 and balancing its protein level. Also, experiments on whole
cell lysates with HA-tagged ubiquitin mutants further conﬁrmed
the ability of TRAF2 to inhibit USP2a on K48-linked – but not K63-
linked – ubiquitin chains (Fig. 7F). This is also supported by knock-
down experiments of USP2a, which impacted on the K63 ubiquitin
chains of RIP1 but not on its K48 chains [5]. To our knowledge this
speciﬁc inhibition of one enzymatic activity of a ubiquitin-speciﬁc pro-
tease has not been observed before. It could be achieved by an induced
conformation change and/or steric hindrance upon binding of TRAF2 to
USP2a. Whilst RIP1 and most other substrates are affected (Fig. 7F),
some protein targets could be excluded and form part of USP2a's role
in other signalling pathways [28–30]. Whilst USP2a and TRAF2 cannot
compete for the ubiquitination of K48-linked ubiquitin chains on RIP1,
they do compete for its K63 ubiquitin chains. Thus, the ratio of their
protein levels determines survival or cell death in the TNF signalling
pathway (Fig. 8A). The association of USP2a with RIP1 and TRAF2 is
minor in normal cells and increases when TNF-α is applied. This
would facilitate the competition for the K63 ubiquitin chains of RIP1
and the inhibition of TRAF2 on the enzymatic activity of USP2a for
RIP1's K48-chains (Fig. 9). This could also explain why in TRAF2−/−
cells the level of RIP1 appears to be unchanged (Fig. 8B). Alternativelyor in addition, TRAF2 could be only one of the inhibitors of USP2a that
is overcome when USP2a is overexpressed but whose knock‐down is
not sufﬁcient for the activation of USP2a.
4.1. Conclusion
With our study on the two splice isoforms of USP2, USP2a and
USP2c, we have found a number of shared features such as their com-
mon substrates TRAF2 and RIP1, the latter of which is responsible for
both enzymes' activity to cause cell death upon ectopic expression.
On the other hand, when they are downregulated by RNAi only
USP2c and not USP2a induced apoptosis. This is most likely due to a
different range of substrates. Interestingly, we found that one of the
targets, TRAF2, can inhibit the activity of USP2a to release K48 ubiquitin
chains from substrates, which has implications for its effect to mediate
the pro-apoptotic signal from the TNF receptor.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.05.022.
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